Research Article |
Corresponding author: Wamidh H. Talib ( altaei_wamidh@yahoo.com ) Academic editor: Danka Obreshkova
© 2024 Reem Ali Hamed, Wamidh H. Talib.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
|
Background: Breast cancer (BC) is considered the most diagnosed cancer among women globally. This is because of its high possibility of metastasis and high resistance to chemotherapy. Cisplatin is a platinum-based antitumor agent that is used to treat various types of cancer. However, the main obstacle to using this drug is drug resistance. Drug resistance is a cause of most relapses of cancer which eventually lead to death. Nowadays, combining natural products is a trend to overcome drug resistance. Thymoquinone (TQ) is a natural phytochemical that exists mainly in blackseed. It has been used in medicine for decades, especially as an anticancer agent. Silymarin is a milk thistle compound that exhibits anticancer, hepatoprotective, and neuroprotective activity. Hence, the combination of TQ and silymarin could be a probable solution to treat cancer and reduce chemoresistance.
Methods: This study tested this combination on cisplatin-sensitive (EMT6/P) and cisplatin-resistant (EMT6/CPR) mouse mammary cell lines. Apoptotic and antiproliferative activity was assessed for TQ and silymarin in vitro using caspase-3 and [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] (MTT) assays, respectively. An in vivo study was performed to evaluate the effect of TQ and silymarin combination in mice inoculated with EMT6/P and EMT6/CPR cells. The safety profile was also examined using creatinine and liver enzyme assays.
Results: In vitro, the TQ and silymarin combination synergized in both cell lines. Also, this combination caused apoptosis induction at a higher rate than the single treatment in both cell lines. In vivo, TQ and silymarin combination resulted in a remarkable reduction in tumor size and enhanced the cure rate in mice implanted with EMT6/P and EMT6/CPR cell lines. According to the safety profile results, TQ and silymarin combination was safe.
Conclusion: In conclusion, the combination of TQ and silymarin provides a promising solution in treating BC resistant to cisplatin by inducing apoptosis. Further studies are needed to define the exact anticancer mechanisms of this combination.
breast cancer resistance, thymoquinone, silymarin, cisplatin resistance
Cancer is the leading cause of mortality and a significant reason for the decrease in life expectancy in all countries around the world (
Breast cancer (BC) is considered the most diagnosed cancer among women globally. This is because of its high possibility of metastasis and high resistance to chemotherapy (
Breast cancer is associated with numerous risk factors. Among these are reproductive factors, which are late marriage, getting first childbirth at delayed age and the age of menopause which correlates strongly to the disease development (
Cisplatin is a platinum-based antitumor agent that is used to treat various types of cancer (
In this research, we have focused on using combination therapy to deal with cisplatin resistance. The combination could be between one herbal constituent with another or with a chemotherapeutic agent (
Thymoquinone (TQ) is a natural phytochemical, that exists mainly in black seed (Nigella sativa; family Ranunculaceae) or black cumin, and it has been widely used in the treatment/prevention of several types of cancer including BC (
To date, no study investigated the effect of combination therapy between thymoquinone and silymarin to overcome cisplatin resistance in BC.
Pure TQ and silymarin were supplied from Sigma Aldrech. Their CAS-No were 490-91-5 and 65666-07-1 respectively. Sensitive mice mammary cell line (EMT-6/P) and cisplatin resistant cell line (EMT-6/CPR) were attained from the European Collection of Cell Cultures (Salisbury, UK). In our examination, minimum essential medium (MEM) (Caisson, USA) was used to culture both cells. The media which was supplied as 500 ml bottle was supplemented with 5 ml of L-glutamine (Eurobio, France), 0.5 ml of non-essential amino acids (Caisson, USA), 50 ml of 10% fetal bovine serum (Sigma, USA), 5 ml of penicillin-streptomycin solution (Eurobio, France) and 0.5 ml of 0.1% Gentamycin (Sigma, USA). Cells were incubated at 37 °C, with 5% carbon dioxide, and 95% humidity.
In order to separate the adherent cells from the walls of the cell culture flask, the trypsinization method was applied. This is accomplished by adding trypsin ethylene diamine tetra acetic acid (trypsin EDTA) (Eurobio, France) with phosphate buffer saline (PBS) (Eurobio, France). For MTT assay, cell counting was performed by using trypan blue (0.4%) (Sigma, USA). Dimethyl sulfoxide (DMSO) (Alpha Chemika, India). To conserve tumors after vivisection, buffered formalin (10%) (S.D. Fine-Chem ltd, India) was employed.
Besides, to measure the percentage of viable cells, MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5- diphenyltetrazolium bromide) assay kit (Sigma, USA) was utilized. A Colorimetric Caspase-3 Assay Kit (Invitrogen ThermoFisher, USA) with a catalog number: BMS2012INST was applied to detect apoptosis. For ALT serum level assessment, Alanine aminotransferase ALAT (GPT) FS kit (BioMajesty, Germany) was used. For AST serum level assessment, aspartate aminotransferase ASAT(GOT) FS kit (BioMajesty, Germany) was utilized. Furthermore, a Creatinine FS assay kit (BioMajesty, Germany) was performed to measure Creatinine serum levels.
Regarding the MTT assay procedures, TQ and silymarin were dissolved directly in the medium with DMSO (less than 1%) to produce a concentration of 2000 µM as a working solution. These concentrations were selected depending on previous testing conducted in our laboratory (
The positive control, cisplatin (Ebewe Pharma, Austria), was given as a stock solution of 50 mg per 100 mL (0.5 mg/mL) as it is already prepared as a drug in the market. In order to achieve the requisite concentrations of 100 µM down to 0.8 µM in single treatment experiments for both cell lines, further dilutions of the stock solution manipulation MEM were prepared before use (
In combination treatment, 66 µM stock solution of TQ was prepared to produce a serial dilution of 50% to 0.51 µM with fixed dose of silymarin (106.63 µM) in EMT-6/CPR cells. While in EMT-6/P cells, 29.58 µM of TQ stock solution was prepared to generate a serial dilution of 50% to reach 0.23 µM with fixed dose of silymarin (142.40 µM). For silymarin, a stock solution of 106.63 µM was prepared to produce a serial dilution down to 0.83 µM with fixed dose of TQ (66 µM) in EMT-6/CPR cells. While in EMT-6/P cells, 142.40µM of silymarin stock solution was ready to dilute it down to 1.11 µM with fixed dose of TQ (29.58 µM).
MTT (the tetrazolium salt, 3, [4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) is a colorimetric reduction test (Sigma, USA) (
The term “IC₅” refers to the drug concentration needed to kill or inhibit cells by 50% as compared to untreated cells, which suggests that at that concentration, the inhibitory substrate only exerts 50% of its maximum inhibitory action. The statistical software for the social sciences (SPSS) version 26 (Chicago, IL, US) was used in our experiment to compute and evaluate IC₅₀ values. To determine the IC₅₀ values for both single and combination treatments, a nonlinear regression test was performed on the data.
To calculate the combination index (CI) of the combinations of TQ and silymarin against the two cell lines (EMT6/P and EMT6/CPR), we applied an equation published previously (Ichite et al. 2009):
CI = (D) 1/(Dx) 1 + (D) 2/(Dx) 2 + a (D) 1 (D) 2/(Dx) 1 (Dx) 2
Where:
(Dx) 1 = IC₅₀ of TQ alone
(D) 1 = IC₅₀ of TQ in combination with silymarin
(Dx) 2 = IC₅₀ of silymarin alone
(D) 2 = IC₅₀ of silymarin in combination with TQ
a = 0 for mutually exclusive or 1 for mutually nonexclusive interaction.
According to the literature study, silymarin and TQ each have a unique mode of action for fighting cancer. Therefore, in CI calculations, we used the mutually nonexclusive model, where α = 1. CI results are explained as follows:
If CI > 1.3 that shows antagonism, CI = 1.1–1.3 represents moderate antagonism, CI = 0.9–1.1 indicates additive effect, CI = 0.8–0.9 shows slight synergism, CI = 0.6–0.8 reveals moderate synergism, CI = 0.4–0.6 means synergism, CI = 0.2–0.4 reveals strong synergism, and CI < 0.1 reveals a very strong synergism (
To compare the resistant cell line to the sensitive cell line, we used the term “resistance fold”. It described the times of change in the concentration required to achieve 50% death in the resistant cell line against the sensitive cell line. The resistance fold is determined in this study by comparing the IC₅₀ values between the resistant EMT-6/CPR and the sensitive EMT-6/P cell lines using the formula:
Resistance fold = IC₅₀ of Resistant Cell Line ∕ IC₅₀ of Parental Cell Line.
By subjecting EMT-6/P and EMT-6/CPR cell lines to a range of cisplatin concentrations (208.33, 104.16, 52.08, 26.04,13.02,6.51, 3.25, 1.62 µM) for 48 hours, the anti-proliferative assay (MTT) was carried out to assess the cisplatin-mediated anti-proliferative effect on these cell lines.
The tested cell line (EMT-6/CPR) was taken out of the liquid nitrogen tank, thawed at 37 °C, and grown in flasks measuring 75 cm2 and containing 15 ml of MEM. The cultivated cells were then incubated overnight at 37 °C, 5% CO2, and 95% humidity. Using 0.5 mL trypsin-EDTA and 1 mL 1X PBS, cells were separated from the flask walls and allowed to incubate for 2–3 minutes. Cells were then transferred to 15-mL sterile centrifuge tubes, rinsed with 5 mL MEM, and centrifuged at 1000 rpm for 10 minutes at 4 °C. Cells (pellets) were resuspended in 5 mL MEM and counted.
The cells were seeded at a density of 100,000 cells/mL in a 75 cm2 area that was pre-labelled with the cell type, passage number, and date. Five flasks were made, and they underwent a 24-hour incubation period to ensure optimal adhesion and growth. At that point, the treatments were dissolved in fresh media, and the old media was discarded. The negative control flask contained only MEM. A single dose of TQ (10 µM) and a single dose of silymarin (10 µM) were added to flasks two and three. A combined dose of (10 µM) TQ and (10 µM) silymarin was in flask four. Eventually, a dose of cisplatin (0.50 mg/ml) was added to flask five.
The flasks were then incubated for 48 hours. After incubation, the old medium was taken out of each flask and discarded. The flasks were then cleaned with 2 ml of PBS before each was given 1 ml of trypsin to separate the cells. The entire 5 mL was then transferred to a centrifugation type (15 mL) and centrifuged at 1000 rpm at 4 °C for 10 min. After adding 4 ml of the new medium, we added trypsin. Pellets of cells are now prepared for testing for caspase-3 activity.
According to the kit’s instructions, the lysis buffer was made, and then 1 ml of it was added to every 5*106 cells. The tubes were then gently shaken while being incubated for one hour at room temperature. The tubes were then centrifuged for 15 minutes at 1000×. Then, 100 µL, 100 µL, and 140 µL, of distilled water were added to the blank, standard, and sample wells respectively. Then, 10 ml of each sample in each well was added in two separate additions. The plate was then covered and shaken for three hours at room temperature. Using the washing buffer previously produced per the kit instructions, the microwell strips were washed six times after three hours, each time adding 140 µL to each well containing the blank, standard, and samples. After the final wash, the microwell strip was tapped on a paper towel to remove the extra buffer. The substrate solution (tetramethylbenzidine) was then added to each well at a volume of 100 µL. The microplate was then kept at room temperature for almost ten minutes, or until the highest standard turned dark blue. The stopping solution (1M phosphoric acid) was then added to each well at a volume of 100 µL. After that, a spectrophotometer employing a 450nm wavelength immediately scanned the plate.
This investigation utilized 35 female Balb/C strain mice, aged 4–6 weeks, weighing between 21 and 25 g each. The animal house of the Applied Science Private University in Amman, Jordan, provided mice. The Research and Ethical Committee of Applied Science University approved all animal experimentation methods in accordance with accepted ethical standards. The approval No. was 2023-PHA-11. Separate cages with bedding made of wood shavings were used to house the animals. The animal housing was set up with a constant temperature of 25 C, a 50–60% humidity range, continuous air ventilation, and 12-hour cycles of light and dark.
On female Balb/C mice with EMT-6/P and EMT-6/CPR tumors, we carried out the in vivo part. Based on research that was published in the literature, the doses of TQ, silymarin, and cisplatin were selected. For TQ, an intraperitoneal dose of 25 mg/kg (0.625 mg/mouse) was chosen. It was given every day for 10 days based on the dosage used by Fatfat et al. (Fatfat et al. 2019). In contrast, Kim et al. study (Kim et al. 2021) stated that silymarin dosage was a daily intraperitoneal injection of 50 mg/kg (1.25 mg/mouse) for 10 days. Cisplatin dose was based on the literature of Talib et al. (
EMT-6/CPR and EMT-6/P cells were defrosted, cultivated, separated, calculated and seeded using MEM. After that, they were kept in the incubator to grow for 24 h. Using trypsinization method, exponentially growing EMT-6/P and EMT-6/CPR cells were collected, washed, and resuspended in MEM, at a density of 1.5 × 10⁶ cells / ml. Then, viable cells were assessed using trypan blue exclusion technique. Each female BALB/C mouse received a subcutaneous injection of 1.5 × 105 tumor-inducing cells in a 0.1 mL medium. Following the injection of cancer cells, the tumor-bearing mice got the therapies on day 15, after the tumors had grown for 14 days. Tumor dimensions were measured with a digital caliper and tumor volumes were calculated using the method below:
Tumor volume = A × B2 × 0.5
Where:
A = length of the longest aspect of the tumor.
B = the length of the tumor aspect perpendicular to A.
It was decided to choose tumors of comparable sizes, and the average tumor volume for each group was approximately matched. EMT-6/P, a parent BC cell line, was injected into the right side of each mouse, and EMT-6/CPR, a cisplatin-resistant BC cell line, was injected into the left side of each mouse. After 14 days of the tumor injection, the treatment began. In this study, 35 tumor-bearing mice were employed, and they were split into five groups (n = 7 for each group), Fig.
Three-time periods during the treatment period days (1, 5, and 10) were used to quantify the tumor volumes. The following calculation was used to compute the percent change in tumor volumes when comparing beginning and final volumes:
% Tumour change = ((F−I)/ I) * 100%
Where F is the final tumor volumes, and I represent the initial tumour volumes. After 10 days of treatment, mice were sacrificed by cervical dislocation, and blood samples were taken retroorbitally for each group. To maintain the morphology of the tumors, they were excised, weighed, and kept in 10% formalin. For 10 minutes, blood samples were centrifuged at 5000 rpm. The produced serum was transferred to a fresh, pre-labelled Eppendorf tube for each sample. For the next studies, serum samples were kept at -20 C.
The blood levels of the liver enzymes ALT and AST were measured for TQ, silymarin, cisplatin, and their combinations that were previously described. In addition, the negative control group was assessed to determine the levels of liver damage caused by the utilized therapies. Alanine aminotransferase ALAT (GPT) FS kits and aspartate aminotransferase ASAT (GOT) FS kits were used to evaluate ALT and AST after serum samples were collected. To create functioning reagents, reagents were combined according to the protocol’s instructions. In ALAT (GPT) FS kit, the first reagent was a combination of Tris (hydroxymethyl) aminomethane buffer, L-Alanine, and Lactate dehydrogenase (LDH). While the second reagent was a mixture of 2-Oxoglutarate along with Nicotinamide adenine dinucleotide (NADH). In ASAT (GOT) FS kit, Tris (hydroxymethyl) aminomethane buffer, L-Aspartate, Malate dehydrogenase (MDH) and LDH were in the first reagent. The second reagent was a combination of 2-Oxoglutarate and NADH. Then, to achieve the reaction’s ideal temperature, working reagents were incubated at 37 °C. Next, 100 µL of each sample were combined with 1 mL of the working reagent in a single-use cuvette. After one minute of incubation, the initial absorbance at time zero was noted. Readings of absorbance were taken after 0, 1, 2, and 3 minutes. The spectrophotometer was calibrated to zero absorbance using distilled water and synced to read absorbance at 340 nm. Working reagents were used as blanks as well.
We also assessed the levels of kidney injury via the several treatments; creatinine level was measured for TQ, silymarin, cisplatin and their combinations beside the negative control group. The level of creatinine in the obtained serum samples was then determined using a creatinine kit. The standard (S) was ready to use. In accordance with the guidelines, reagents were combined to create functioning reagents. In order to accurately determine the reaction temperature, the working reagent was then incubated at 37 °C. After mixing 100 µL of each sample with 1 mL of the working solution in a disposable cuvette, absorbance measurements were taken after 30 and 90 seconds. Utilizing distilled water, the spectrophotometer was adjusted to zero absorbance and calibrated to read absorbance at 505 nm. Additionally, working reagents were used as blank samples.
SEM (Standard Error of Mean) was used to represent the results as a mean ±SEM. The IC₅₀ values for TQ, silymarin, cisplatin, and their combinations against EMT-6/P and EMT-6/CPR cell lines were really obtained. Additionally, ANOVA nonlinear regression was used in SPSS (Statistical Package for the Social Sciences, Chicago, IL, USA) version 26 to statistically examine the IC₅₀ results. To determine the statistical significance between groups, GraphPad prism 8 software was used. It was considered a significant difference between the groups when the probability level (P-value) was less than 0.05 (P-value < 0.05). At least two separate animal experimentation studies were carried out, with a minimum of six animals per group.
The MTT test was carried out on EMT-6 cisplatin-sensitive parent BC cells (EMT-6/P) and EMT-6 cisplatin-resistant BC cell lines (EMT-6/CPR) to assess TQ’s efficacy as a single treatment. As shown in Fig.
To evaluate the effectiveness of silymarin as a single treatment, the MTT test was performed on EMT-6 cisplatin-sensitive parent BC cells (EMT-6/P) and EMT-6 cisplatin-resistant BC cell lines (EMT-6/CPR) compared to the vehicle control, Fig.
The anti-proliferative assay (MTT) was applied to evaluate the cisplatin-mediated anti-proliferative effect on both EMT-6/P and EMT-6/CPR cell lines. That was achieved by exposing EMT-6/P and EMT-6/CPR cell lines to a range of cisplatin concentrations (208.33, 104.16, 52.08, 26.04,13.02,6.51, 3.25, 1.62 µM) for 48 hours. Then, it was determined that the cisplatin concentration needed to inhibit cell growth by 50% (IC₅₀) was 26.50 ± 0.01 µM for the EMT-6/P cell line and 70 ± 0.006 µM for the EMT-6/CPR cell line. According to the aforementioned equation, IC₅₀ values of cisplatin in both cell lines were used to determine the resistance fold. The findings revealed that EMT-6/CPR cells were 2.64 times more resistant to cisplatin than EMT-6/P cells, as shown in Fig.
IC₅₀ values of TQ, Silymarin and Cisplatin on EMT-6/P, EMT-6/CPR cell lines, along with the combination index (CI), interpretation and resistance folds.
Cell line | IC₅₀ of Single TQ (µM) | IC₅₀ of Single Silymarin (µM) | IC₅₀ of Cisplatin (µM) | TQ IC₅₀ in combination with silymarin (µM) | Silymarin IC₅₀ in combination with TQ (µM) | CI | Interpretation |
---|---|---|---|---|---|---|---|
EMT6/P | 59.16 | 284.8 | 26.5 | 29.95 | 25.23 | 0.632 | Synergism |
EMT6/CPR | 132 | 213.27 | 70 | 1.83 | 0.939 | 0.018 | Very strong synergism |
Resistant folds | 2.23 | 0.75 | 2.64 | 0.061 | 0.037 |
To assess the inhibitory impact of TQ and silymarin combination treatment, EMT-6/P, and EMT-6/CPR cell lines were treated with different doses of TQ and a constant concentration of silymarin. Also, these cells were treated with different doses of silymarin and a fixed dose of TQ; both treatments lasted for 48 hours.
According to the MTT assay findings, Figs
The 50% inhibitory concentrations (IC₅₀) of the combination treatment were 25.23 ± 16.5 µM of silymarin and 29.95 ± 3.5 µM of TQ in EMT-6/P and 0.939 ± 0.308 µM of silymarin and 1.83 ± 1.01 µM of TQ in EMT-6/CPR.
Several doses of TQ are administered to both cell lines with a fixed dosage of silymarin using the MTT test to acquire the IC₅₀ values, which allow the CI to be calculated using the previously described equation and further explanation. The same method was applied in the combination of several doses of silymarin with a fixed dose of TQ in both cell lines.
The combination test analysis revealed that the combination therapy had a synergistic impact on EMT-6/P cells and a strong synergism on EMT-6/CPR cells, with CIs of (0.632) and (0.018), respectively (Table
The MTT test was used to compare the IC₅₀ values of TQ, silymarin, and cisplatin combination therapy for both cell lines in order to assess EMT-6/CPR resistance to these therapies. Table
A colorimetric caspase-3 test kit was used to assess the apoptotic effect of TQ, silymarin, cisplatin, and their combinations on caspase-3 levels in EMT-6/CPR cell line. As clarified in Fig.
In contrast to the negative control group, which had an increase in tumor size of 47.62%, all the treated groups displayed a significant reduction (P-value < 0.05) in tumor size Fig.
Results of TQ, silymarin, their combinations, and cisplatin regarding tumor size changes, percentages of change in tumor size and average tumor weight in EMT-6/P cell line (n = 7).
Treatment group EMT-6/P | Av. initial tumor size (mm3) | Av. final tumor size (mm3) | %Change in tumor size (%) | Mice with no detectable tumor (%) | Av. tumor weight (g) |
---|---|---|---|---|---|
Control | 292.66 | 432.06 | 47.62 | 0 | 0.261 |
TQ | 210.46 | 27.65 | -86.86 | 100 | 0.00 |
Silymarin | 228.90 | 71.75 | -68.65 | 57.14 | 0.156 |
Cisplatin | 443.85 | 252.41 | -43.12 | 16.66 | 0.239 |
TQ + Silymarin | 249.33 | 18.42 | -92.60 | 100 | 0.029 |
As a result, the same treatment procedures were used on EMT-6/CPR. Table
Results of TQ, Silymarin, their combinations and, cisplatin regarding tumor size changes, percentages of change in tumor size and average tumor weight in EMT-6/CPR cell line (n = 7).
Treatment group for EMT-6/CPR | Av. Initial tumor size (mm3) | Av. Final tumor size (mm3) | change in tumor size (%) | Mice with no detectable tumor (%) | Av. tumor weight (g) |
---|---|---|---|---|---|
Control | 327.25 | 522.91 | 59.78 | 0 | 0.757 |
TQ | 259.73 | 142.64 | -45.07 | 42.85 | 0.193 |
Silymarin | 436.27 | 348.21 | -20.18 | 14.28 | 0.373 |
Cisplatin | 285.31 | 203.83 | -28.55 | 16.66 | 0.296 |
TQ + Silymarin | 361.05 | 157.39 | -56.40 | 42.85 | 0.250 |
Since ALT and AST assays are regarded as indicators for liver damage, blood levels of liver enzymes were evaluated for all treated groups with TQ, silymarin, their combinations, and cisplatin, in addition to the negative (untreated) control, Table
Serum ALT, AST and Cr levels for groups with different treatments, negative control treated with only vehicle.
Treatment groups | ALT (IU/L) | AST (IU/L) | Cr (mg/dl) |
---|---|---|---|
Control | 47.9 ± 2.1 | 212.4 ± 15.3 | 0.25 ± 0.01 |
TQ | 41.1 ± 6.4 | 245.4 ± 7.0 | 0.24 ± 0.02 |
Silymarin | 43.8 ± 1.7 | 222.8 ± 3.5 | 0.25 ± 0.01 |
Cisplatin | 38.1 ± 1.2 | 187 ± 18 | 0.26 ± 0.01 |
TQ + silymarin | 40.8 ± 5.5 | 230.8 ± 11.7 | 0.23 ± 0.01 |
In the case of creatinine, normal levels of serum creatinine were observed between the healthy mice and the other mouse groups that received the previously mentioned therapies, except the cisplatin group which showed a significant increase in creatinine level to 0.27 mg/dl (Figs
BC incidence continues to rise despite decades of epidemiological, laboratory, and clinical studies. BC is still the major cancer-related cause of disease burden for women, impacting one in every 20 people worldwide and up to one in every eight in high-income nations (
Thus, in our study, TQ and silymarin natural products were compared to cisplatin as single treatments or in combination. In particular, they were examined in vitro on EMT-6/P and EMT-6/CPR BC cell lines and in vivo on female Balb/C mice injected with both EMT-6/P and EMT-6/CPR BC cell lines. According to our findings, TQ inhibited the viability of EMT-6/P and EMT-6/CPR cell lines in a concentration-dependent manner. These findings are consistent with Talib et al. study, where they examined TQ on EMT-6/P BC cell line and the investigated results displayed a dose-dependent anti-cancer activity (
Apoptosis has been extensively documented as a key process of controlled death that takes place not just in response to external stress or cell damage but also during normal development and morphogenesis (
It is generally known that caspase-3 is regarded as a crucial enzyme in the execution of apoptosis, and is therefore often targeted to detect apoptosis (
In accordance with the in vitro findings, this study discovered that TQ reduced tumor size in both cell lines in vivo to 86.86% and 45.07% in EMT-6/P and EMT-6/CPR, respectively. The treatment was intraperitoneal (i.p.) injection of 25 mg/kg of TQ for 10 days in a daily basis treatment, Tables
Silymarin exhibited a reduction in the tumor size in EMT-6/P significantly to 68.65% after daily i.p. injection of 50 mg/kg for 10 days, Table
In this study, several combination strategies were examined. Firstly, our TQ and silymarin combination which reduced tumor size in the studied cell lines in vivo significantly with the highest percentage of reduction. The shrinking in tumor sizes were 92.6% and 56.4% in EMT-6/P and EMT-6/CPR, respectively. This was attained after i.p. daily injection of 25 mg/kg TQ and 50 mg/kg of silymarin for 10 days Tables
Cisplatin is one of the most effective and popular medications for the treatment of different solid malignancies. Cisplatin’s antineoplastic properties are primarily a result of its capacity to cross-link with DNA, preventing transcription and replication (
In terms of safety, anticancer drugs’ safety profiles are frequently evaluated to determine their toxicity (
Based on the information provided, we draw the conclusion that the combination of TQ and silymarin demonstrated a synergistic anticancer effect against both the parent (EMT-6/P) and resistant (EMT-6/CPR) cell lines in vitro and in vivo through apoptosis induction and caspas-3 activation better than each treatment alone. But when TQ and silymarin were combined in novel ways, the tumor size reduction was superior to that of a single therapy in both cell lines. These combinations are less harmful to the liver and kidneys than traditional cisplatin treatment. Such unusual combinations make it worthwhile broadening the scope of study to ascertain additional information in order to benefit from it further in breast cancer therapy.
Research and development are a never-ending process, with constant scrutiny for useful, futuristic, and significant results that add to a greater understanding of cancer prevention and therapy. As a result, the following recommendations for further work on this subject are provided:
RAH contributed to design the study, the writing and editing of the report, and the analysis and interpretation of the data. WT contributed to conceptualize, plan, and revise the experiments.
The Research and Ethical Committee of Applied Science University approved all animal experimentation techniques in accordance with standard ethical principles. The Institutional Review Board (IRB) panels at the IRB authorized the methods used to collect tumor tissue samples (Approval number: 2023-PHA-11). This was all conducted in conformity with the moral guidelines established by the 1964 Helsinki Declaration and its ensuing revisions.
The authors express their sincere gratitude to Drs. Asmaa’ Mahmod and Sara Abuarab for their essential advice during the laboratory work. Additionally, we would like to thank Mr. Salem Al Shawabkeh for helping to handle the animals throughout the in vivo research. We would also want to acknowledge Mr. Fawzi Alarian for his ongoing assistance in supplying the required resources and his efforts to sterilize all equipment. This work was supported by The Deanship of Scientific Research at Applied Science Private University.